Literature DB >> 9255558

Genetic polymorphism of cytochrome P450 as a biomarker of susceptibility to environmental toxicity.

J Y Hong1, C S Yang.   

Abstract

Cytochrome P450 (CYP) enzymes are responsible for the metabolism of numerous xenobiotics and endogenous compounds, including the metabolic activation of most environmental toxic chemicals and carcinogens. Both metabolic and genetic polymorphisms have been identified for human CYP enzymes. The association of CYP genetic polymorphism and human cancer risk, and susceptibility to environmental hazards, have received increasing attention. This article briefly reviews the approaches and methods currently used in CYP genetic polymorphism studies. In addition, the current status and perspectives of using CYP genetic polymorphism as a biomarker of individual susceptibility to cancer and environmental toxicity are discussed.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9255558      PMCID： PMC1470024          DOI： 10.1289/ehp.97105s4759

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN： 0091-6765            Impact factor:   9.031


  31 in total

1.  A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking.

Authors:  D Sesardic; A R Boobis; R J Edwards; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

Review 2.  Metabolic polymorphisms.

Authors:  A K Daly; S Cholerton; W Gregory; J R Idle
Journal:  Pharmacol Ther       Date:  1993 Feb-Mar       Impact factor: 12.310

3.  Cytochrome P450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma.

Authors:  M W Yu; A Gladek-Yarborough; S Chiamprasert; R M Santella; Y F Liaw; C J Chen
Journal:  Gastroenterology       Date:  1995-10       Impact factor: 22.682

4.  CYP1A1 mRNA levels as a human exposure biomarker: use of quantitative polymerase chain reaction to measure CYP1A1 expression in human peripheral blood lymphocytes.

Authors:  J P Vanden Heuvel; G C Clark; C L Thompson; Z McCoy; C R Miller; G W Lucier; D A Bell
Journal:  Carcinogenesis       Date:  1993-10       Impact factor: 4.944

5.  Cytochrome P4502E1 genetic polymorphisms and risk of nasopharyngeal carcinoma: results from a case-control study conducted in Taiwan.

Authors:  A Hildesheim; C J Chen; N E Caporaso; Y J Cheng; R N Hoover; M M Hsu; P H Levine; I H Chen; J Y Chen; C S Yang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1995-09       Impact factor: 4.254

6.  Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites.

Authors:  M A Butler; N P Lang; J F Young; N E Caporaso; P Vineis; R B Hayes; C H Teitel; J P Massengill; M F Lawsen; F F Kadlubar
Journal:  Pharmacogenetics       Date:  1992-06

7.  Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.

Authors:  F J Gonzalez; R C Skoda; S Kimura; M Umeno; U M Zanger; D W Nebert; H V Gelboin; J P Hardwick; U A Meyer
Journal:  Nature       Date:  1988-02-04       Impact factor: 49.962

8.  Analysis of cytochrome P450 2E1 genetic polymorphisms in relation to human lung cancer.

Authors:  S Kato; P G Shields; N E Caporaso; H Sugimura; G E Trivers; M A Tucker; B F Trump; A Weston; C C Harris
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1994-09       Impact factor: 4.254

Review 9.  Metabolic activation of toxins: tissue-specific expression and metabolism in target organs.

Authors:  O Pelkonen; H Raunio
Journal:  Environ Health Perspect       Date:  1997-06       Impact factor: 9.031

10.  Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility.

Authors:  A K Daly; S Cholerton; M Armstrong; J R Idle
Journal:  Environ Health Perspect       Date:  1994-11       Impact factor: 9.031
View more
  4 in total

Review 1.  Approaches for assessing risks to sensitive populations: lessons learned from evaluating risks in the pediatric population.

Authors:  Ronald N Hines; Dana Sargent; Herman Autrup; Linda S Birnbaum; Robert L Brent; Nancy G Doerrer; Elaine A Cohen Hubal; Daland R Juberg; Christian Laurent; Robert Luebke; Klaus Olejniczak; Christopher J Portier; William Slikker
Journal:  Toxicol Sci       Date:  2009-09-21       Impact factor: 4.849

2.  Genetic polymorphisms in CYP1A1, GSTM1, GSTP1 and GSTT1 metabolic genes and risk of lung cancer in Asturias.

Authors:  M Felicitas López-Cima; Sara M Alvarez-Avellón; Teresa Pascual; Ana Fernández-Somoano; Adonina Tardón
Journal:  BMC Cancer       Date:  2012-09-27       Impact factor: 4.430

Review 3.  Neurotoxicity of brominated flame retardants: (in)direct effects of parent and hydroxylated polybrominated diphenyl ethers on the (developing) nervous system.

Authors:  Milou M L Dingemans; Martin van den Berg; Remco H S Westerink
Journal:  Environ Health Perspect       Date:  2011-02-04       Impact factor: 9.031

Review 4.  Cytogenetic markers of susceptibility: influence of polymorphic carcinogen-metabolizing enzymes.

Authors:  H Norppa
Journal:  Environ Health Perspect       Date:  1997-06       Impact factor: 9.031
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.